Langer-backed Kala scores $90M IPO as it lines up a pair of NDAs

Kala Phar­ma­ceu­ti­cals has now joined the ranks of this year’s biotech IPO class, hit­ting the range and rais­ing $90 mil­lion af­ter pric­ing shares at $15.

That cash will now help fund the fi­nal leg of two Phase III stud­ies for two dif­fer­ent dos­es of KPI-121 and the first round of com­mer­cial­iza­tion work that the biotech hopes lies ahead. Their lead drug is be­ing stud­ied for in­flam­ma­tion and pain fol­low­ing oc­u­lar surgery as well as the tem­po­rary re­lief of the signs and symp­toms of dry eye dis­ease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER